Genentech Company Profile
✉ Email this page to a colleague
What is the competitive landscape for GENENTECH, and when can generic versions of GENENTECH drugs launch?
GENENTECH has nine approved drugs.
There are fifty-six US patents protecting GENENTECH drugs.
There are eight hundred and forty-four patent family members on GENENTECH drugs in fifty-three countries and eighty-six supplementary protection certificates in nineteen countries.
Summary for Genentech
International Patents: | 844 |
US Patents: | 56 |
Tradenames: | 6 |
Ingredients: | 6 |
NDAs: | 9 |
Patent Litigation for Genentech: | See patent lawsuits for Genentech |
PTAB Cases with Genentech as patent owner: | See PTAB cases with Genentech as patent owner |
Drugs and US Patents for Genentech
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Genentech Inc | ROZLYTREK | entrectinib | CAPSULE;ORAL | 212725-001 | Aug 15, 2019 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-003 | Jan 11, 2017 | AB | RX | Yes | Yes | 8,084,475 | ⤷ Try a Trial | ⤷ Try a Trial | |||
Genentech Inc | XOFLUZA | baloxavir marboxil | TABLET;ORAL | 210854-001 | Oct 24, 2018 | DISCN | Yes | No | 10,633,397 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-003 | Jan 11, 2017 | AB | RX | Yes | Yes | 8,648,098 | ⤷ Try a Trial | ⤷ Try a Trial | |||
Genentech Inc | ESBRIET | pirfenidone | CAPSULE;ORAL | 022535-001 | Oct 15, 2014 | AB | RX | Yes | Yes | 7,816,383 | ⤷ Try a Trial | ⤷ Try a Trial | |||
Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-003 | Jan 11, 2017 | AB | RX | Yes | Yes | 7,566,729 | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Genentech
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-001 | Jan 11, 2017 | 9,561,217 | ⤷ Try a Trial |
Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-002 | Jan 11, 2017 | 9,561,217 | ⤷ Try a Trial |
Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-003 | Jan 11, 2017 | 9,561,217 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for GENENTECH drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 267 mg, 534 mg and 801 mg | ➤ Subscribe | 2018-10-15 |
International Patents for Genentech Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Israel | 219056 | ⤷ Try a Trial |
Hong Kong | 1153647 | ⤷ Try a Trial |
Japan | 7423515 | ⤷ Try a Trial |
Israel | 263004 | ⤷ Try a Trial |
Mexico | 2013003139 | ⤷ Try a Trial |
Philippines | 12017502414 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Genentech Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2620436 | C02620436/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: BALOXAVIRUM MARBOXILUM; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 67426 21.02.2020 |
1934174 | 1690019-3 | Sweden | ⤷ Try a Trial | PRODUCT NAME: COBIMETINIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE, IN PARTICULAR COBIMETINIB HEMIFUMARATE; REG. NO/DATE: EU/1/15/1048 20151124 |
1934174 | CA 2016 00021 | Denmark | ⤷ Try a Trial | PRODUCT NAME: COBIMETINIB, EVENTUELT I EN HVILKEN SOM HELST FORM BESKYTTET AF GRUNDPATENTET, DER INDBEFATTER FARMACEUTISK ACCEPTABLE SALTE OG SOLVATER, SAERLIGT COBIMETINIB HEMIFUMARAT; REG. NO/DATE: EU/1/15/1048 20151124 |
1789390 | C01789390/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: VISMODEGIB; REGISTRATION NO/DATE: SWISSMEDIC 62497 30.05.2013 |
2620436 | 132021000000038 | Italy | ⤷ Try a Trial | PRODUCT NAME: BALOXAVIR MARBOXIL O UN SUO SALE O SOLVATO FARMACEUTICAMENTE ACCETTABILE(XOFLUZA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/20/1500, 20210108 |
2176231 | LUC00191 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: ENTRECTINIB OU LES ISOMERES, TAUTOMERES, OU SELS PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/20/1460 20200803 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.